| [1] |
Wang Y, Zhao L, Gao L, et al. Health policy and public health implications of obesity in China [J]. Lancet Diabetes Endocrinol, 2021, 9(7): 446-461.
|
| [2] |
Nauck MA, Quast DR, Wefers J, et al. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update [J]. Diabetes Obes Metab, 2021, 23(Suppl 3): 5-29.
|
| [3] |
Battelino T, Bergenstal RM, Rodriguez A, et al. Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial [J]. Lancet Diabetes Endocrinol, 2022, 10(6): 407-417.
|
| [4] |
Wilding J, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity [J]. N Engl J Med, 2021, 384(11): 989-1002.
|
| [5] |
Lautenbach A, Wernecke M, Huber TB, et al. The potential of semaglutide once-weekly in patients without type 2 diabetes with weight regain or insufficient weight loss after bariatric surgery-a retrospective analysis [J]. Obes Surg, 2022, 32(10): 3280-3288.
|
| [6] |
Holst JJ. The physiology of glucagon-like peptide 1 [J]. Physiol Rev, 2007, 87(4): 1409-1439.
|
| [7] |
Hwang JI, Yun S, Moon MJ, et al. Molecular evolution of GPCRs: GLP1/GLP1 receptors [J]. J Mol Endocrinol, 2014, 52(3): T15-T27.
|
| [8] |
Strain WD, Frenkel O, James MA, et al. Effects of semaglutide on stroke subtypes in type 2 diabetes: post hoc analysis of the randomized SUSTAIN 6 and PIONEER 6 [J]. Stroke, 2022, 53(9): 2749-2757.
|
| [9] |
Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide [J]. Front Endocrinol (Lausanne), 2019, 10: 155.
|
| [10] |
Smits MM, Van Raalte DH. Safety of semaglutide [J]. Front Endocrinol (Lausanne), 2021,12: 645563.
|
| [11] |
Christou G A, Katsiki N, Blundell J, et al. Semaglutide as a promising antiobesity drug [J]. Obes Rev, 2019, 20(6): 805-815.
|
| [12] |
O'Neil PM, Birkenfeld AL, McGowan B, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial [J]. Lancet, 2018, 392(10148): 637-649.
|
| [13] |
Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: The STEP 3 randomized clinical trial [J]. JAMA, 2021, 325(14): 1403-1413.
|
| [14] |
Davies M, Faerch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial [J]. Lancet, 2021, 397(10278): 971-984.
|
| [15] |
Andreadis P, Karagiannis T, Malandris K, et al. Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis [J]. Diabetes Obes Metab, 2018, 20(9): 2255-2263.
|
| [16] |
Gibbons C, Blundell J, Tetens HS, et al. Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes [J]. Diabetes Obes Metab, 2021, 23(2): 581-588.
|
| [17] |
Rosenstock J, Wysham C, Frias JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial [J]. Lancet, 2021, 398(10295): 143-155.
|
| [18] |
Heise T, Mari A, DeVries JH, et al. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial [J]. Lancet Diabetes Endocrinol, 2022,10(6): 418-429.
|
| [19] |
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity [J]. N Engl J Med, 2022, 387(3): 205-216.
|
| [20] |
Thomas MK, Nikooienejad A, Bray R, et al. Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes [J]. J Clin Endocrinol Metab, 2021,106(2): 388-396.
|
| [21] |
Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes[J]. N Engl J Med, 2021, 385(6): 503-515.
|
| [22] |
Mingrone G, Panunzi S, De Gaetano A, et al. Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial [J]. Lancet, 2021,397(10271):293-304.
|
| [23] |
Ejarque M, Guerrero-Perez F, de la Morena N, et al. Role of adipose tissue GLP-1R expression in metabolic improvement after bariatric surgery in patients with type 2 diabetes [J]. Sci Rep, 2019, 9(1): 6274.
|
| [24] |
Larraufie P, Roberts GP, McGavigan AK, et al. Important role of the GLP-1 axis for glucose homeostasis after bariatric surgery [J]. Cell Rep, 2019, 26(6): 1399-1408.
|
| [25] |
Svane MS, Jorgensen NB, Bojsen-Moller KN, et al. Peptide YY and glucagon-like peptide-1 contribute to decreased food intake after Roux-en-Y gastric bypass surgery [J]. Int J Obes (Lond), 2016, 40(11): 1699-1706.
|
| [26] |
Wallenius V, Dirinck E, Fandriks L, et al. Glycemic control after sleeve gastrectomy and Roux-en-Y gastric bypass in obese subjects with type 2 diabetes mellitus [J]. Obes Surg, 2018, 28(6): 1461-1472.
|
| [27] |
Webb DL, Abrahamsson N, Sundbom M, et al. Bariatric surgery - time to replace with GLP-1? [J]. Scand J Gastroenterol, 2017, 52(6-7): 635-640.
|
| [28] |
Zhang L, Tan WH, Chang R, et al. Perioperative risk and complications of revisional bariatric surgery compared to primary Roux-en-Y gastric bypass [J]. Surg Endosc, 2015, 29(6): 1316-1320.
|
| [29] |
Wharton S, Kuk JL, Luszczynski M, et al. Liraglutide 3.0 mg for the management of insufficient weight loss or excessive weight regain post-bariatric surgery [J]. Clin Obes, 2019, 9(4): e12323.
|
| [30] |
Pajecki D, Halpern A, Cercato C, et al. Short-term use of liraglutide in the management of patients with weight regain after bariatric surgery [J]. Rev Col Bras Cir, 2013, 40(3): 191-195.
|